- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Bethlehem Today
By the People, for the People
OraSure Technologies Stock Crosses Above 200-Day Moving Average
The medical device company's stock price has risen above a key technical indicator.
Mar. 14, 2026 at 7:09am
Got story updates? Submit your updates here. ›
OraSure Technologies, Inc. (NASDAQ:OSUR), a Bethlehem, Pennsylvania-based diagnostic and medical device company, saw its stock price cross above its 200-day moving average on Friday. The stock traded as high as $3.15 before closing at $2.97, with a trading volume of 646,154 shares.
Why it matters
Crossing above the 200-day moving average is often seen as a bullish technical indicator, suggesting the stock may be entering a period of sustained upward momentum. However, the company has received a 'Reduce' rating from analysts, who cite concerns about its financial performance.
The details
OraSure Technologies develops and commercializes point-of-care and self-testing products, including its flagship OraQuick rapid HIV test. The company's stock has a 50-day simple moving average of $2.81 and a 200-day simple moving average of $2.80, with a market capitalization of $205.32 million, a price-to-earnings ratio of -3.19, and a beta of 0.88.
- OraSure Technologies' stock crossed above its 200-day moving average on Friday, March 14, 2026.
- The company's 50-day simple moving average is $2.81.
The players
OraSure Technologies, Inc.
A Bethlehem, Pennsylvania-based diagnostic and medical device company specializing in the development, manufacture, and commercialization of point-of-care and self-testing products, including its flagship OraQuick rapid HIV test.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
The takeaway
The crossing of OraSure Technologies' stock price above its 200-day moving average is a potentially positive technical signal, but the company's overall financial performance and analyst ratings suggest caution is warranted for investors.
